In recent years, platform clinical trials have gained substantial support and provide an efficient way of testing multiple compounds in a single and consistent framework. In the traditional setting, each new compound requires independent proof-of -concept, phase 2A and 2B trials to be designed and conducted. In this setting patients, are often randomized between the new treatment and control, with the same control utilized in many studies. In contrast, platform clinical trials utilize a master protocol with each new compound added through an intervention specific appendix. This innovative approach leverages the common control, patient outcomes and recruitment centers to improve efficiency in terms of operations, analysis and decision making. However, a variety of factors can greatly impact the realized gains from a platform study. In this talk I provide a brief introduction to platforms studies and will look at how innovative approach, such as hierarchical models, can help to mitigate risk factors. The last part of the presentation I will introduce an R package that for simulating platform trials.